Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In SituE. Shelley Hwang, Doreen M. Agnese, Meredith Witten et al.|JAMA|2024Cited by 75
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancerCarey K. Anders, Jonathan S. Serody, Mark G. Woodcock et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 28
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In SituAnn H. Partridge, Kimberly Strickland, Terry Hyslop et al.|JAMA Oncology|2024Cited by 16